Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles EBioMedicine Year : 2022

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

Ana Zarubica

Abstract

BackgroundThere is an urgent need of a new generation of vaccine that are able to enhance protection against SARS-CoV-2 and related variants of concern (VOC) and emerging coronaviruses.MethodsWe identified conserved T- and B-cell epitopes from Spike (S) and Nucleocapsid (N) highly homologous to 38 sarbecoviruses, including SARS-CoV-2 VOCs, to design a protein subunit vaccine targeting antigens to Dendritic Cells (DC) via CD40 surface receptor (CD40.CoV2).FindingsCD40.CoV2 immunization elicited high levels of cross-neutralizing antibodies against SARS-CoV-2, VOCs, and SARS-CoV-1 in K18-hACE2 transgenic mice, associated with viral control and survival after SARS-CoV-2 challenge. A direct comparison of CD40.CoV2 with the mRNA BNT162b2 vaccine showed that the two vaccines were equally immunogenic in mice. We demonstrated the potency of CD40.CoV2 to recall in vitro human multi-epitope, functional, and cytotoxic SARS-CoV-2 S- and N-specific T-cell responses that are unaffected by VOC mutations and cross-reactive with SARS-CoV-1 and, to a lesser extent, MERS epitopes.InterpretationWe report the immunogenicity and antiviral efficacy of the CD40.CoV2 vaccine in a preclinical model providing a framework for a pan-sarbecovirus vaccine.FundingsThis work was supported by INSERM and the Investissements d'Avenir program, Vaccine Research Institute (VRI), managed by the ANR and the CARE project funded from the Innovative Medicines Initiative 2 Joint Undertaking (JU).
Fichier principal
Vignette du fichier
S2352396422002432.pdf (3.89 Mo) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03692817 , version 1 (22-07-2024)

Licence

Identifiers

Cite

Séverin Coléon, Aurélie Wiedemann, Mathieu Surénaud, Christine Lacabaratz, Sophie Hue, et al.. Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. EBioMedicine, 2022, 80, pp.104062. ⟨10.1016/j.ebiom.2022.104062⟩. ⟨hal-03692817⟩
53 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More